Background In clinical trials of idiopathic pulmonary fibrosis, rates of all-cause mortality are
low. Thus prospective mortality trials are logistically very challenging, justifying the use of …

Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with
inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was …

Pirfenidone is an antifibrotic agent that has been evaluated in three multinational phase 3
trials in patients with idiopathic pulmonary fibrosis (IPF). We analysed pooled data from the …

Rationale: Respiratory-related hospitalizations of patients with idiopathic pulmonary fibrosis
(IPF) are more frequent than those for acute IPF exacerbations and are associated with poor …

Background Pirfenidone is an oral antifibrotic agent that has been shown to reduce the
decline in lung function in patients with idiopathic pulmonary fibrosis (IPF). We performed an …

Background: The American Thoracic Society, European Respiratory Society, Japanese
Respiratory Society, and Asociación Latinoamericana del Tórax convened to update clinical …

Background Pirfenidone is an antifibrotic compound approved for the treatment of idiopathic
pulmonary fibrosis (IPF). We present our real-world experience in terms of Pirfenidone's …

Background In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced
disease progression, as measured by the decline in forced vital capacity (FVC) or vital …

Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor prognosis. In the last
decades pirfenidone an anti-inflammatory and anti-fibrotic agent has shown benefit in inhibit …

Background and objective Pirfenidone is an oral antifibrotic agent that is approved in several
countries for the treatment of idiopathic pulmonary fibrosis (IPF). We performed a …